Ivantis Inc. specializes in developing innovative medical devices for the treatment of glaucoma, specifically targeting patients undergoing cataract surgery. The company's flagship product, the Hydrus Microstent, is a minimally invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure in patients with mild to moderate primary open-angle glaucoma. By integrating this device during cataract surgery, Ivantis aims to improve patient outcomes by reducing or eliminating the need for glaucoma medications. The company operates in the ophthalmology market, serving healthcare providers and patients across the United States, United Kingdom, Canada, Australia, and Singapore. Ivantis generates revenue through the sale of its Hydrus Microstent to medical institutions and eye care professionals. The business model focuses on leveraging clinical trial data to demonstrate the efficacy and safety of its products, thereby driving adoption among ophthalmologists and surgeons.

Keywords: glaucoma, Hydrus Microstent, cataract surgery, intraocular pressure, MIGS, ophthalmology, medical devices, eye care, clinical trials, healthcare.